A novel <info type="SequenceVariant">mutation</info> screening system for <info type="DiseaseOrPhenotypicFeature">Ehlers-Danlos Syndrome</info>, <info type="DiseaseOrPhenotypicFeature">vascular type</info> by <info type="ChemicalEntity">high-resolution melting curve analysis</info> in combination with <info type="ChemicalEntity">small amplicon genotyping</info> using <info type="GeneOrGeneProduct">genomic DNA</info>.

<info type="DiseaseOrPhenotypicFeature">Ehlers-Danlos syndrome</info>, <info type="DiseaseOrPhenotypicFeature">vascular type</info> (<info type="DiseaseOrPhenotypicFeature">vEDS</info>) (MIM #<info type="SequenceVariant">130050</info>) is an <info type="DiseaseOrPhenotypicFeature">autosomal dominant disorder</info> caused by <info type="GeneOrGeneProduct">type III procollagen gene</info> (<info type="GeneOrGeneProduct">COL3A1</info>) <info type="SequenceVariant">mutations</info>. Most <info type="GeneOrGeneProduct">COL3A1</info> <info type="SequenceVariant">mutations</info> are detected by using <info type="GeneOrGeneProduct">total RNA</info> from patient-derived <info type="CellLine">fibroblasts</info>, which requires an invasive <info type="DiseaseOrPhenotypicFeature">skin biopsy</info>. <info type="ChemicalEntity">High-resolution melting curve analysis</info> (<info type="ChemicalEntity">hrMCA</info>) has recently been developed as a post-PCR <info type="SequenceVariant">mutation scanning method</info> which enables simple, rapid, cost-effective, and highly sensitive <info type="SequenceVariant">mutation screening</info> of large <info type="GeneOrGeneProduct">genes</info>. We established a <info type="ChemicalEntity">hrMCA</info> method to screen for <info type="GeneOrGeneProduct">COL3A1</info> <info type="SequenceVariant">mutations</info> using <info type="GeneOrGeneProduct">genomic DNA</info>. PCR <info type="GeneOrGeneProduct">primers pairs</info> for <info type="GeneOrGeneProduct">COL3A1</info> (52 <info type="ChemicalEntity">amplicons</info>) were designed to cover all coding regions of the 52 <info type="GeneOrGeneProduct">exons</info>, including the <info type="GeneOrGeneProduct">splicing sites</info>. We used 15 <info type="GeneOrGeneProduct">DNA samples</info> (8 <info type="GeneOrGeneProduct">validation samples</info> and 7 <info type="GeneOrGeneProduct">samples</info> of clinically suspected <info type="DiseaseOrPhenotypicFeature">vEDS</info> patients) in this study. The eight known <info type="GeneOrGeneProduct">COL3A1</info> <info type="SequenceVariant">mutations</info> in <info type="GeneOrGeneProduct">validation samples</info> were all successfully detected by the <info type="ChemicalEntity">hrMCA</info>. In addition, we identified five novel <info type="GeneOrGeneProduct">COL3A1</info> <info type="SequenceVariant">mutations</info>, including one <info type="SequenceVariant">deletion</info> (<info type="SequenceVariant">c.2187delA</info>) and one <info type="SequenceVariant">nonsense mutation</info> (<info type="SequenceVariant">c.2992C>T</info>) that could not be determined by the conventional <info type="GeneOrGeneProduct">total RNA</info> method. Furthermore, we established a <info type="ChemicalEntity">small amplicon genotyping</info> (<info type="ChemicalEntity">SAG</info>) method for detecting three high frequency coding-region <info type="SequenceVariant">SNPs</info> (<info type="SequenceVariant">rs1800255:G>A</info>, <info type="SequenceVariant">rs1801184:T>C</info>, and <info type="SequenceVariant">rs2271683:A>G</info>) in <info type="GeneOrGeneProduct">COL3A1</info> to differentiate <info type="SequenceVariant">mutations</info> before sequencing. The use of <info type="ChemicalEntity">hrMCA</info> in combination with <info type="ChemicalEntity">SAG</info> from <info type="GeneOrGeneProduct">genomic DNA</info> enables rapid detection of <info type="GeneOrGeneProduct">COL3A1</info> <info type="SequenceVariant">mutations</info> with high efficiency and specificity. A better understanding of the <info type="GeneOrGeneProduct">genotype-phenotype correlation</info> in <info type="GeneOrGeneProduct">COL3A1</info> using this method will lead to improve in <info type="DiseaseOrPhenotypicFeature">diagnosis</info> and <info type="DiseaseOrPhenotypicFeature">treatment</info>.